KY-62, a polyene analog of amphotericin B, for treatment of murine candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 1, 1998, Pages 147-150

  Graybill, John R ^a,b   Najvar, Laura K ^b   Fothergill, Annette ^b   Hardin, Thomas ^b   Rinaldi, Michael ^a,b   Lambros, Chris ^c   Regen, Steven L ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c LEHIGH UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DERIVATIVE; FLUCYTOSINE; FLUOROURACIL; KY 62; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031962720     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.1.147     Document Type: Article

References (25)

1. Adler-Moore, J. 1994. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14(Suppl. 5):S3-S7.
2. 2+ on the stages of the antifungal effects of amphotericin B and filipin. Antimicrob. Agents Chemother. 18:593-597.
3. Brajtburg, J., W. G. Powderly, G. S. Kobayashi, and G. Medoff. 1990. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34:183-188.
4. de Marie, S., R. Janknegt, and I. A. J. M. Bakker-Woudenberg. 1994. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33:907-916.
5. Ellis, W. G., R. A. Sobel, and S. L. Nielsen. 1982. Leukoencephalopathy in patients with amphotericin B methyl ester. J. Infect. Dis. 146:125-137.
6. Graybill, J. R. 1986. Animal models for treatment of cryptococcosis, p. 131-145. In O. Zak and M. A. Sande (ed.), Experimental models in antimicrobial chemotherapy. Academic Press, New York, N.Y.
7. Graybill, J. R., P. C. Craven, L. Mitchell, and D. J. Drutz. 1978. Interaction of chemotherapy and immune defense in experimental murine cryptococcosis. Antimicrob. Agents Chemother. 14:659-667.
8. Hoeprich, P. D. 1982. Amphotericin B methyl ester and leukoencephalopathy: the other side of the coin. J. Infect. Dis. 146:173-176.
9. Hoeprich, P. D. 1992. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin. Infect. Dis. 14(Suppl. 1):S114-S119.
10. Hunter, P., P. Murdock, G. Randall, S. Anthony, S. Jones, A. Everett, C. Winch, and I. Burbidge. 1992. Comparative activity in vivo and toxicity of a new polyene, BRL 49594A and amphotericin B (amB), abstr. 1043, p. 284. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Jangnegt, R., S. de Marie, I. A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. 1995. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23:279-291.
12. Jullien, S., A. Contrepois, J. E. Sligh, Y. Domart, P. Yeni, J. Brajtburg, G. Medoff, and J. Bolard. 1989. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phosphohpids. Antimicrob. Agents Chemother. 33:345-349.
13. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, and M. A. Gordon. 1994. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect. Immun. 62:2761-2772.
14. Mills, W., R. Chopra, D. C. Linch, and A. H. Goldstone. 1994. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br. J. Haematol. 86:754-760.
15. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing for yeasts: proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Racis, S. P., O. J. Plescia, H. M. Geller, and C. P. Schaffner. 1990. Comparative toxicities of amphotericin B and its monomethyl ester derivative on glial cells in culture. Antimicrob. Agents Chemother. 34:1360-1365.
17. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, and National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24: 235-247.
18. Schmitt, H. J. 1993. New methods of delivery of amphotericin B. Clin. Infect. Dis. 17(Suppl. 2):S501-S506.
19. Tohyama, M., K. Kawakami, and A. Saito. 1996. Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrob. Agents Chemother. 40:1919-1923.
20. Van der Horst, C., M. Saag, G. Cloud, R. Hamill, R. Graybill, J. Sobel, P. Johnson, C. Tuazon, T. Kerkering, J. Fisher, H. Henderson, J. Stansell, D. Mildvan, L. Riser, D. Schneider, R. Hafner, C. Thomas, B. Weisinger, and B. Moskovitz. 1995. Part I. Randomized double blind comparison of amphotericin B plus flucytosine (AMB+FC) to AMB alone (step 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of acute cryptococcal meningitis in patients with AIDS, abstr. 1216, p. 244. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Vertut-Doï, A., S.-I. Ohnishi, and J. Bolard. 1994. The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrob. Agents Chemother. 38:2373-2379.
22. Walsh, T. J., and D. M. Dixon. 1989. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis, and treatment. Eur. J. Epidemiol. 5:131-142.
23. Williams, D. M., J. R. Graybill, and D. J. Drutz. 1979. Experimental chemotherapy of histoplasmosis in nude mice. Am. Rev. Respir. Dis. 120:837-842.
24. Wilson, E., L. Thorson, and D. P. Speert. 1991. Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob. Agents Chemother. 35:796-800.
25. Yamashita, K., V. Janout, E. M. Bernard, D. Armstrong, and S. L. Regen. 1995. Micelle/monomer control over the membrane-disrupting properties of an amphiphilic antibiotic. J. Am. Chem. Soc. 117:6249-6253.